Xeris Biopharma Reports Third Quarter 2021 Financial Results and Other Highlights
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/13/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
Xeris Pharmaceuticals Inc. (XERS) Misses Q3 EPS by 2c
November 10, 2021 7:22 AM ESTXeris Pharmaceuticals Inc. (NASDAQ: XERS) reported Q3 EPS of ($0.39), $0.02 worse than the analyst estimate of ($0.37). Revenue for the quarter came in at $11 million versus the consensus estimate of $11.03 million.
For earnings history and earnings-related data on Xeris Pharmaceuticals Inc. (XERS) click here.
... More